Arbutus Biopharma and Genevant Sciences are broadening the scope of their patent infringement claims against Moderna with ...

The S&P 500 has soared in recent times, delivering two consecutive years of double-digit gains, and investors -- from ...

Bexhill’s De La Warr Pavilion presents Ssh Ow, the first major solo exhibition in a UK public gallery in a decade by ...

Over the weekend the World Health Organization (WHO) announced a new setback in Uganda's Ebola Sudan outbreak. The country ...

Late last week in Morbidity and Mortality Weekly Report, authors from the Centers for Disease Control and Prevention (CDC) ...

So far 70 confirmed human cases of H5N1 infection have been reported, following a widespread outbreak across bird and cattle ...

Genevant Sciences and Arbutus Biopharma (ABUS) filed five international lawsuits seeking to enforce patents protecting their innovative LNP ...

As STAT’s Helen Branswell writes, mRNA vaccines are the fastest to make and the easiest to mass produce.

BASEL, Switzerland and VANCOUVER, British Columbia and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a r ...

Highly pathogenic avian influenza continues to devastate poultry flocks throughout the United States, as well as cause ...

HHS is re-evaluating a nearly $600 million contract with Moderna to develop and test vaccines against flu viruses that could ...

U.S. involvement in WHO flu meetings, the UK's approval of Moderna's RSV vaccine, efforts against a measles outbreak in Texas ...